| Market Cap | 420.53M | P/E | - | EPS this Y | -27.30% | Ern Qtrly Grth | - |
| Income | -41.95M | Forward P/E | -132.14 | EPS next Y | 90.00% | 50D Avg Chg | 1.00% |
| Sales | 5.78M | PEG | -0.33 | EPS past 5Y | - | 200D Avg Chg | 40.00% |
| Dividend | N/A | Price/Book | 5.27 | EPS next 5Y | 40.00% | 52W High Chg | - |
| Recommedations | 2.90 | Quick Ratio | 6.73 | Shares Outstanding | 45.46M | 52W Low Chg | 167.00% |
| Insider Own | 19.04% | ROA | -23.11% | Shares Float | 31.48M | Beta | 1.32 |
| Inst Own | 80.10% | ROE | -50.36% | Shares Shorted/Prior | 0.92M/1.03M | Price | 9.25 |
| Gross Margin | 66.85% | Profit Margin | - | Avg. Volume | 1,505,521 | Target Price | 9.50 |
| Oper. Margin | -719.69% | Earnings Date | Nov 8 | Volume | 178,496 | Change | 0.11% |
Kindred Biosciences, Inc., a commercial-stage biopharmaceutical company, engages in developing therapies for pets. Its product pipeline focuses on biologics for a range of indications primarily in dogs and cats. The company offers Mirataz, a mirtazapine transdermal ointment for the management of weight loss in cats; and Zimeta, a dipyrone injection for the control of fever in horses. It also develops KIND-016, a monoclonal antibody for the treatment of atopic dermatitis in dogs; KIND-032, a monoclonal antibody targeting interleukin-4 (IL-4) receptor for the treatment of atopic dermatitis in dogs; KIND-025 a canine fusion protein targeting IL-4 and IL-13 for atopic dermatitis in dogs; KIND-030, a monoclonal antibody targeting canine parvovirus for the prophylactic indication in dogs; KIND-509, an antibody for canine inflammatory bowel disease in dogs; KIND-510a, a long-acting feline recombinant erythropoietin being developed for the management of non-regenerative anemia in cats; and KIND-511, an anti-tumor necrosis factor treatment for newborn foals. The company was incorporated in 2012 and is headquartered in Burlingame, California. As of August 27, 2021, Kindred Biosciences, Inc. operates as a subsidiary of Elanco Animal Health Incorporated.
| Lake Street | Hold | Jun 17, 21 |
| HC Wainwright & Co. | Neutral | Jun 17, 21 |
| Aegis Capital | Hold | Jun 16, 21 |
| Aegis Capital | Buy | Jan 26, 21 |
| Cantor Fitzgerald | Overweight | Jul 29, 20 |
| Stifel | Buy | Mar 17, 20 |
| H.C. Wainwright | Buy | Mar 17, 20 |
| B. Riley | Neutral | Jul 16, 19 |
| Barclays | Overweight | Jun 11, 19 |
| Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Park West Asset Management LLC | 10% Owner 10% Owner | Jun 07 | Sell | 6.87 | 414,983 | 2,850,933 | 6,000,002 | 06/07/21 |
| Park West Asset Management LLC | 10% Owner 10% Owner | Feb 01 | Sell | 5.16 | 213,772 | 1,103,064 | 6,414,985 | 02/01/21 |
| Bevers Denise | Director Director | Jan 15 | Option | 0.32 | 13,023 | 4,167 | 13,023 | 01/15/21 |
| Bevers Denise | Director Director | Jan 15 | Sell | 5 | 13,023 | 65,115 | 01/15/21 | |
| Bevers Denise | Director Director | Jan 08 | Option | 0.32 | 39,069 | 12,502 | 39,069 | 01/08/21 |
| Bevers Denise | Director Director | Jan 08 | Sell | 5 | 39,069 | 195,345 | 01/08/21 | |
| Bevers Denise | Director Director | Oct 08 | Option | 0.32 | 12,508 | 4,003 | 12,508 | 10/08/20 |
| Bevers Denise | Director Director | Oct 08 | Sell | 5.01 | 12,508 | 62,665 | 10/08/20 | |
| Bevers Denise | Director Director | Sep 24 | Option | 0.32 | 515 | 165 | 515 | 09/24/20 |
| Bevers Denise | Director Director | Sep 24 | Sell | 5 | 515 | 2,575 | 09/24/20 |